Evidence map›Paper›PMID 30817270›Full record

ArticleTurkish journal of urology2019

Can the expression level of PIWIL 2 gene be a serum marker for prostate cancer? A single-center prospective study.

Halil Tosun, Abdullah Demirtaş, Gökhan Sönmez, Şevket Tolga Tombul, Hilal Akalın, Yusuf Özkul

Abstract read
In one paragraph

Article in Turkish journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Halil TosunDepartment of Pediatric Urology, Ankara Children's Health and Disease Hemotology-Oncology Training and Research Hospital, Ankara, Turkey.ORCID http://orcid.org/0000-0002-0289-869X
Abdullah DemirtaşDepartment of Urology, Erciyes University School of Medicine, Kayseri, Turkey.ORCID http://orcid.org/0000-0001-9102-5518
Gökhan SönmezClinic of Urology, Kayseri City Hospital, Kayseri, Turkey.ORCID http://orcid.org/0000-0001-8391-1050
Şevket Tolga TombulDepartment of Urology, Erciyes University School of Medicine, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-5398-4088
Hilal AkalınDepartment of Medical Genetics, Erciyes University School of Medicine, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-2580-836X
Yusuf ÖzkulDepartment of Medical Genetics, Erciyes University School of Medicine, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-3044-5663

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of the present study was to evaluate the predictive value of the serum expression level of Piwi-like 2 (PIWIL2), a stem cell protein, for prostate cancer (PCa). MATERIALS AND

methodThis randomized and prospective study included a total of 60 volunteers between 50 and 75 years old. Cases were assigned to three groups according to prostate-specific antigen (PSA) elevations and pathology reports, with 20 participants in each group. The first group included patients with a PSA level of >4 ng/dL and with PCa, the second group included patients with a PSA level of >4 ng/dL and with benign prostate hyperplasia, and the third group included patients with a PSA level of ≤4 ng/dL and with benign prostate hyperplasia. The levels of serum PSA and PIWIL2 expressions were compared between the groups.

resultsThe median serum PSA levels were 28.5 (4.6-98.1) ng/mL, 8.89 (4.3-24.1) ng/mL, and 2.4 (0.3-3.8) ng/mL for groups 1, 2, and 3, respectively. The PSA levels were significantly different between the groups (p<0.001). The median PIWIL2 gene expression levels were 2.54 (0.28-9.27), 2.27 (0.6-9.38), and 1.17 (0.26-3.07) for groups 1, 2, and 3, respectively. The PIWIL2 gene expression level was found to be lower in patients with a PSA level of <4 (p=0.02). No significant difference was observed between patients with and without cancer among those with a PSA level of ≥4 (p>0.05). Patients diagnosed with cancer were grouped according to the criteria of the International Society of Urological Pathology (ISUP), and PIWIL2 gene expression was observed to be significantly higher among patients with ISUP of >3 than among those with ISUP of ≤3 (p=0.04).

conclusionIn our study, it was observed that the serum level of PIWIL2 gene expression could not be a diagnostic indicator of PCa; however, it could be a beneficial prognostic indicator particularly for progressed disease.

Identifiers

PMID30817270
PMCPMC7595026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.